Read the First Edition of The Lens, a new magazine by LSI arrow-icon
Published January 2007 | Forecasts through 2012
U.S. Breast Disease Diagnosis and Therapy Markets
Reports Graph
Overview
The breast disease diagnosis and therapy markets are poised for substantial and sustainable growth, according to this new report from Life Science Intelligence (LSI). The report, Breast Disease Diagnosis and Therapy Markets, 2007, finds that the $550 million U.S. digital mammography segment is expected to grow more than 50% annually during the next 3 years as digital technology replaces analog. In addition, the $167 million US vacuum-assisted biopsy segment will also experience dramatic growth reaching over $350 million in the U.S. by 2012.

This in-depth report provides a deep and discrete analysis of the patients, procedures, technologies and companies driving growth and innovation in the U.S. markets for breast disease diagnosis and therapy. Coverage includes:

Non-Interventional Breast Disease Diagnosis - Mammography, computer-aided diagnosis, magnetic resonance imaging, diagnostic ultrasound, screening ultrasound, and various other diagnostic methods.

Interventional Breast Disease Diagnosis - Ultrasound-guided breast biopsy, stereotactic-guided breast biopsy, spring-loaded and vacuum-assisted biopsy techniques, and other methods.

Breast Disease Therapy - Treatment of benign breast disease including surgical intervention, cryoablation, thermoablation, and percutaneous excision. Treatment of malignant breast disease including surgical excision and breast brachytherapy.

Buy U.S. Breast Disease Diagnosis and Therapy Markets
Companies Covered
Aurora Imaging
CR Bard
Cytyc
FujiFilm
General Electric
Hologic
Johnson & Johnson (Ethicon Endo-Surgery)
Philips
SenoRx
Siemens
Suros Surgical
Toshiba

Order individually or subscribe and
get a complete intel platform.

Trusted By The Companies Pioneering What’s Next